Abeona Therapeutics (NASDAQ:ABEO) PT Set at $30.00 by HC Wainwright
HC Wainwright set a $30.00 target price on Abeona Therapeutics (NASDAQ:ABEO) in a research note published on Thursday, January 4th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts have also issued reports on the stock. ValuEngine lowered shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Zacks Investment Research lowered shares of Abeona Therapeutics from a buy rating to a hold rating in a report on Thursday, November 23rd. Jefferies Group restated a buy rating and issued a $28.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Maxim Group set a $35.00 price objective on shares of Abeona Therapeutics and gave the stock a buy rating in a report on Monday, November 20th. Finally, SunTrust Banks initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, November 8th. They set a buy rating and a $26.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $26.40.
Shares of Abeona Therapeutics (ABEO) opened at $16.30 on Thursday. Abeona Therapeutics has a 12 month low of $4.50 and a 12 month high of $22.75.
A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Geode Capital Management LLC raised its holdings in Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the period. Schwab Charles Investment Management Inc. purchased a new position in Abeona Therapeutics in the second quarter valued at approximately $264,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $190,000. State of Wisconsin Investment Board acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $122,000. Finally, Bank of New York Mellon Corp grew its position in Abeona Therapeutics by 138.5% in the second quarter. Bank of New York Mellon Corp now owns 99,996 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 58,067 shares in the last quarter. Hedge funds and other institutional investors own 41.97% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.